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HIV experts unanimously agreed on three
aspects of HIV management during the 8th
national Conference on Retroviruses and
Opportunistic Infections (8th CROI), held in
Chicago during Feb 3-5 of this year. The three
points of agreement were: promoting voluntary
testing, improving access to care, and the
need for new approaches to eradicating latent
HIV after initiating treatment with HAART. 
This article reviews presentations at the con-
ference that were relevant to the management
of HIV in corrections, including (1) viral eradi-
cation; (2) new aspects of the HHS guidelines
for HIV management including management
of drug resistance and the application of geno-
typing in clinical practice, (3) new drugs in the
HIV treatment pipeline, and (4) structured
treatment interruption. 
Viral Eradication: The
Elusive Holy Grail?
Bob Siliciano of Johns Hopkins University
reviewed the status of HIV eradication in the
Monday opening plenary. It is well known that
Highly Active Antiretroviral Therapy (HAART)
effectively interrupts replication of the virus in
activated T cells in the blood, reducing viral
loads but not completely eradicating the virus.
The identity of the reservoir of latent virus has
been debated. Dr. Silicano focused his talk on
the population of memory T cells that harbor
latent virus in a form that is directly integrated
into the T cell DNA. When these cells divide,
as they do at a low rate approximately every 6
months, the viral genes are transferred to
daughter T memory cells. Current antiretroviral
medications do not have any impact on the
perpetuation of this viral reservoir, due to their
action on viral proteins (not host and viral gene
replication). Thus, no amount of HAART will
ever eradicate the virus from the T memory
cell reservoir. Newer treatments that attack
integrated viral DNA are needed if viral eradi-
cation is to be achieved. 
There was one bright note in this discussion:
new evidence from Dr. Silicano’s laboratory
appears to confirm that effective HAART can
reduce viral replication to zero. Patients with a
history of having been adherent to HAART
over several years continued to harbor virus
that was resistant to previously used drugs,
but no new mutations occurred. This data sug-
gests that fully suppressive treatment of HIV
creates a viral reservoir that remains "frozen in
time", with no genetic evidence for new cycles
of virus replication.1
This finding was relevant in the context of
other discussions about drug toxicities and
management of patients with HAART at the
conference. Several speakers discussed the
concept of "substitution" - substituting triple
NRTI or NRTI + NNRTI regimens for the more
potent NRTI + PI regimen when patients
achieve non-detectable viral loads.2 This
observation leads to the next most obvious
study: what would be the impact of attacking
HIV with highly active drugs (three and four
drug regimens including PIs), reducing the
replication to zero, and then substituting a
new, more tolerable, regimen? This concept
was not addressed at the 8th CROI, but stud-
ies are sure to follow.
The New Guidelines: Use
Tools and Consult Experts
Updated US HHS guidelines3 were made
available on the web during the CROI confer-
ence; they are now available at:
http://www.hivatis.org. A yellow-shaded ver-
sion of the guidelines is also available at this
site, highlighting changes from the last docu-
ment. The most important change in the guide-
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New evidence appears to con-
firm that effective HAART can
reduce viral replication to zero.
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lines is to delay the initiation of HIV treat-
ment until absolute CD4 T cell counts are
350 or lower and/or HIV RNA viral loads
are 55,000 or higher (Refer to HEPPigram
Table 2 page 8 ). Some experts disagreed
with this decision, which appears to de-
emphasize well-known data on the risk of
progression to AIDS at higher viral loads
(see Table 1).  Treatment should be initiat-
ed by an HIV treatment expert who takes
into consideration the ’willingness’ of the
individual to begin therapy, the degree of
existing immunodeficiency as determined
the CD4 T cell count, the risk of disease
progression as determined by the CD4 T
cell count and the plasma viral RNA, the
potential benefits and risks of therapy, and
the likelihood of adherence. 
Clinical experts at the CROI meeting cau-
tioned against oversimplification in the
rush to delay treatment. Three key com-
ponents of the guidelines deserve empha-
sis here: (1) treatment should not be ter-
minated in patients who have already
begun treatment based on guidelines dis-
tributed prior to this year; (2) careful mon-
itoring of CD4 T cell count and viral load
are critical components of HIV treatment
and most experts would advise checking
these parameters at least every three
months because patients often experi-
ence sudden declines; (3) use of experts
to prescribe and adjust HIV treatment is
increasingly important. 
CD4 T Cell Count and Viral Load: Tools
for HIV Management
The CD4 T cell count (CD4) and the viral
load (VL) are the two most important tools
in the HIV specialist’s armamentarium.
RNA-PCR (Roche) is the only FDA
approved viral load monitoring tool. These
two lab tests provide information on the
HIV stage of disease and the likelihood of
progression. As can be seen from Table 1,
the chance of progressing to AIDS at a
CD4 of 350 and VL of 50,000 is 36.4%
after three years. Both the CD4 T cell
count and the VL should be measured (at
least twice, to establish a firm baseline)
prior to initiating therapy; the VL should be
repeated between two to eight weeks
after initiation of therapy so as to establish
the rate of decline in response to therapy.
There should be a one-log decrease in VL
at this point to indicate response to thera-
py (this emphasis is new). At eight weeks,
if the VL is detectable (defined using the
ultrasensitive assay as a VL less than 50
copies per ml), adherence should be
checked, and the need to intensify or
change therapy should be considered.
VL and CD4 are also used to monitor the
success of therapy; these tests should be
repeated every three to four months.
Successful therapy is indicated by VL less
than 50 (note the new emphasis on ultra-
sensitive viral load testing).  A VL increase
of three-fold or one log and CD4 T cell
decline in absolute numbers more than
30% percent (or more than 3% change in
CD4 T cell percentage) should be con-
firmed, adherence ascertained, and a
change of therapy should be considered
(see HEPPigram page 7).
Drug-Resistant Viruses Fuel Need for
HIV Drug Sequencing
Viral resistance testing (either genotyping
or phenotyping) is a new recommendation
included the HHS guidelines this year
(see Table 2). Genotyping detects muta-
tions in the virus that are linked to
changes in drug sensitivity. Genotyping is
more rapid than phenotyping, but pheno-
typing is more precise (some mutations
are more or less relevant in vivo). There
was no recommendation to use one over
the other. Furthermore, expert advice on
the interpretation of genotyping results,
and a careful history of prior ART expo-
sure are both recommended. In view of
reports at the CROI that up to 26% of
patients who are recently diagnosed har-
bor resistant virus, genotyping prior to ini-
tiation of therapy may become common-
place, particularly in cases where the
patient may have been exposed to a
heavily pretreated patient. The value of
baseline genotyping in chronically infect-
ed treatment naïve patients is less clear,
as resistant strains tend to fall to unde-
tectable levels in untreated patients.
Interested clinicians should read the HHS
guidelines carefully or review  the HEPP
News on resistance testing (online at
http://www.hivcorrections.org/archives/
sept00). In short, resistance mutations
can be archived and the patient’s history
of prior exposure to ART, their current ART
regimen, and cross-resistance within
classes may have an influence on the out-
come and interpretation of resistance
tests.
Acute HIV Infection
Between 10 and 50% of patients with
acute HIV infection present to clinicians
with symptoms. Less than 20% of these
individuals are correctly identified as hav-
ing acute HIV. Data presented by Bruce
Walker (see STI section, page 4) sug-
gests that early treatment may lower the
"setpoint" of HIV infection, possibly pro-
longing life and potentially permitting the
patient to stop therapy. The duration of
therapy of acute HIV infection is com-
pletely unknown at this time. Expert con-
sultation should be obtained.
New approaches and Re-
evaluations of existing
approaches
Results from 144 weeks of the DPC 006
and DMP 006 studies were presented,
showing that the mean time to failure on
dual NRTI and NNRTI regimens will be
about 6 years. These results supported
the inclusion of efavirenz (Sustiva) in the
list of "first line" treatments in the new
HHS guidelines. Results of studies using
Lopinavir/Ritonavir (Kaletra) as initial ther-
apy were also presented at the CROI,
showing excellent responses. Ritonavir-
boosted PI treatments  Lopinavir/Ritonavir
and Indinavir/Ritonavir were two new
additions to the "recommended therapy"
list this year (see HEPPigram Table 1,
page 7).
visit HEPP News online at www.hivcorrections.org 2
Treatment Update...
(continued from page 1)
Table 1. Risk of Progression to AIDS Defining Illness in Treatment Naïve Patients*
IN PATIENTS WITH CD4 201-350 AND
PLASMA VIRAL LOAD (copies/ml) OF:
RT-PCR
1501-7000
7001-20,000
20,001-55,000
> 55,000
3 Years
0
6.9
36.4
64.4
6 Years
20
44.4
72.2
89.3
% AIDS (AIDS-defining complication)
Continued on page 4
*Data from the Multi-Center AIDS Cohort Study (MACS), adapted from Mellors JW, Rinaldo CR,
Gupta P, et al.  Prognosis in HIV-1 Infection predicted by the quantity of virus in plasma. Science.
1996; 272:1167-1170, for inclusion in US Dept of Health and Human Services. Guidelines for the
use of antiretroviral agents in HIV-infected adults and adolescents. Washington, DC: US Dept of
Health and Human Services; February 2001. P37. Online at http://www.hivatis.org.
Table 2. Test Plasma HIV RNA When the Following Clinical Indications 
are Present:
G Syndrome consistent with acute HIV infection
G Initial evaluation of newly diagnosed HIV infection
G Every 3-4 months in patients not on therapy
G 2-8 weeks after initiation of antiretroviral therapy
G 3-4 months after start of therapy
G Every 3-4 months in patients on therapy
G Significant decline in CD4+ T cells
Dear Colleagues,
The 8th Conference on Retroviruses and Opportunistic Infections (8th CROI) had little to
say about our patients in the correctional system, but provided a startling picture of the
global HIV/AIDS epidemic, of which our patients are an integral part.  
"Just saying no" to sex has the same impact on HIV transmission anywhere in the world, but
differences between the HIV prevalence rates distinguish the impact of "just saying yes" in
North Dakota and the Congo, according to Dr. Kevin DeCock of the Center for Disease
Control.1 In areas of the world where most individuals are unaware of their HIV status until
they are dying from AIDS, these individuals are highly likely to transmit the virus to their sex-
ual partners, who then transmit to others, including their children. The impact of "just saying
yes" without knowledge of HIV infection on sub-Saharan Africa has been catastrophic: AIDS
is decimating the ranks of productive adult workers (including health care workers), impov-
erishing families and dramatically increasing the number of children orphaned by AIDS.
While DeCock decried international response to this human emergency of enormous scale,
he did not mention in his speech problems closer to home - such as the impact of HIV/AIDS
on selected sectors of US populations including African Americans, women, and incarcer-
ated populations, even though there were many parallels.
This issue of HEPP News brings you commentary and news from the 8th CROI that is rel-
evant to clinical practice in the correctional setting. After reviewing this issue, readers should
be able to describe the new changes in the HHS guidelines regarding HIV treatment and
resistance testing, how fusion inhibitors may become part of HIV antiretroviral therapy, and
explain why strategic treatment interruption is not recommended. Our next issue will cover
tuberculosis and HIV infection.
We apologize for the tardiness of this issue, but we have a good excuse! Our layout editor
delivered her first child, a baby boy, on Valentines Day. HEPP News welcomes the new
addition to the staff.
Thank you for your continued support and comments. Be sure to visit us online at
www.HIVcorrections.org! 
Sincerely,
Anne S. De Groot, MD Joseph Bick, MD
1 DeCock K. Keynote Lecture - Heterogeneity and public health in the global HIV/AIDS epi-
demic. 8th CROI; February 4-8, 2001; Chicago, Illinois. Abstract L2. 
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4Improved formulations of ART medications
are permitting researchers to address the
topic of once-daily therapy, an innovation in
treatment that may improve adherence in
correctional settings and methadone pro-
grams. Italian researchers and French
researchers showed outcomes from treat-
ment with once-daily didanosine (Videx,
300 mg), lamivudine (3TC, Epivir, 300 mg),
and efavirenz (Sustiva, 600 mg) in 75
patients naive to antiretroviral therapy.4
There is a growing list of ART drugs that
can be considered for once-daily therapy,
including DDI, 3TC (and newer derivatives),
efavirenz, nevirapine (Viramune), abacavir
(Ziagen) and amprenavir/ritonavir. This
writer believes that these newer, more tol-
erable regimens will result in yet another
revision of the guidelines next year.
New "entry blocking" Treatments
Viral entry into the host cell is a new target
for HIV drugs. However, compounds that
are developed to block entry of virus will be
ineffective against virus that spreads by
syncitia formation (cell-to-cell) and will not
have any effect on non-replicating virus. It is
likely that entry blockers will be used in
combination with existing antiretroviral
agents. Two classes of entry inhibitor are in
development - fusion inhibitors and
chemokine receptor blockers. These drugs
are probably most effective when used in
combination.
Fusion Inhibitors
T-20 (made by Trimeris) is the first member
of the fusion inhibitor class. T-20 is a very
short (39 amino acid) peptide that binds to
one of the two helical domains of gp41.
Gp41 is a spring-loaded HIV-1 protein that
is activated when CD4 binds to HIV gp-120.
The fusion action of gp41 is inhibited if its
two helical domains cannot fold together.
T20 binds to gp41, effectively keeping the
protein from functioning. Unfortunately, this
drug is a peptide, so it cannot be given oral-
ly. It is given as an injection, and more than
10% of patients develop reactions at the
injection site. Previous studies of T20 with-
out HAART showed that resistance is rapid
to develop. However, when used in combi-
nation with other ART, the drug appears to
be effective. In a "late breaker report",
Lalezari reported on a Phase I (dose find-
ing) study of 71 patients receiving combina-
tion HAART and T20. By week 16, patients
participating in the T-20 arms of the study
had 0.5 log lower HIV RNA levels than
patients in the non T-20 arms.5 In the future,
due to the need for injections, T20 will prob-
ably be used only in the setting of extensive
resistance. Trimeris is also developing vari-
ant of this drug, called T-1249.
CCR5 Blockers
Another key protein involved in HIV entry is
CCR5 (chemokine receptor 5). This protein
is ubiquitous on immune cell membranes.
Blocking this receptor is believed to be
safe, and important, since individuals who
have homozygous deletion of this gene
appear not to have any increased suscepti-
bility to infections and are almost complete-
ly resistant to HIV infection. The CCR5
blocking-compound furthest along in devel-
opment is a Shering Plough drug, SCH-C.6
Un-Successful  and Un-Structured
Treatment Interruptions (STI)
Structured treatment interruptions (STI)
were addressed by a number of the speak-
ers at the 8th CROI. The rationale for STI is
that CD4 T cell replication is achieved in
effective HAART, so providers were inter-
ested in whether patients could contain
virus (they cannot) and whether "autovacci-
nation" might improve immune responses
to the virus (they do not). Furthermore,
there is a hope that virus will revert to wild
type (it does not, as resistance mutation are
archived in latently infected T cells). Finally,
STI are viewed by patients as a welcome
respite to therapy - this is probably one of
the main motivators for research in this
area.
STI may have a role in EARLY (before sero-
conversion) treatment of HIV, as reported
by Bruce Walker.7 However, based on the
results reported at the 8th CROI, it is too
early to know whether STI is viable options,
and treatment of acute HIV infection should
be supervised by an HIV specialist. At pre-
sent, no guidelines exist as to whether
treatment may be stopped after initial ther-
apy or whether it should be continued indef-
initely (which would run counter to the HHS
guidelines stating treatment should be
delayed until later in the course of disease).
Therapy-Related Adverse Events
Adverse events were one of the major rea-
sons for changes in the HHS guidelines.
Details on mitochondrial toxicity and hepat-
ic steatosis, fat maldistribution, rash, and
diabetes/pancreatitis are given in the new
guidelines. These topic and neuropathy
were also covered at the 8th CROI. In short,
concern about side effects resulted in
changes in the guidelines for the use of
antiretroviral therapy this year (see
HEPPigram Table 1, page 7 and the
upcoming HEPP News issue in April on
neuropathy).
There’s Always More
A special feature for this month, the Rapid
Report on page 6 has further news from the
conference. In the upcoming issues we will
cover more topics from the 8th CROI such
as neuropathy and the CDC’s new program
on National HIV Prevention.  In the mean-
time, visit the conference website
http://www.retroconference.org/2001 or
Medscape at http://www.medscape.com.
Funding for this conference coverage
was provided by educational grants
from Agouron Pharmaceuticals, DuPont
Pharmaceuticals Company, Hoffman La
Roche, and Boehringer-Ingelheim/Roxane
Laboratories.
* Consultant & Speakers Bureau: Agouron Pharmaceuticals, Dupont, Merck, Roche, Boehringer-Ingelheim/Roxane Laboratories
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Treatment Update...
(continued from page 2)
STI are viewed by patients as 
a welcome respite to therapy -
this is probably one of 
the main motivators for
research in this area.
Spotlight: Directly Observed Therapy for HIV Therapy in Corrections: Ready or Not?
5
POINT
By David A. Wohl, M.D.*, Director, Central Prison Infectious
Disease Service, UNC Central Prison Hospital, North  Carolina
Department of Corrections
Reprinted with permission from the National AIDS Treatment
Advocacy Project.
While on the face of it, these results seem to be a resounding
endorsement for DOT, several questions lurk. Although all the
incarcerated subjects received DOT, it is not clear this was
responsible for their excellent responses (above the enviable
rates seen among the free patients).  There are many con-
founding factors that could have contributed to the inmates’ suc-
cess including the regimented structure of prison life, the influ-
ence of  correctional medical staff or just simply having ’three
hots and a cot’ and (relatively) limited access to crack cocaine.
The differences between the two groups of patients extend
beyond the presence or absence of DOT and, therefore, DOT
alone cannot be regarded as the crucial determinant of the
observed results.  In the North Carolina Department of
Corrections, we have found DOT adds nothing to self-adminis-
tration of antiretrovirals (Wohl DA, Stephenson B, et al.
Adherence to Directly Observed Therapy (DOT) of
Antiretrovirals in a State Prison System [357]. Infectious
Disease Society of America, New Orleans, 2000).   In fact,
many inmates complain that DOT renders them conspicuous as
being HIV-infected as they stand in line for medication and
therefore, opt not to present for DOT.  Under such conditions,
DOT may present an obstacle rather than a path to adherence.
Before DOT is used as an intervention to enhance adherence,
some prospective investigation on both sides of the barbed wire
is warranted beyond this interesting first step.
COUNTERPOINT
By David Thomas, M.D.**, Director of Health Services, Florida
Department of Corrections
As a co-author of this presentation and the person responsible
for all of the Health Services in the Florida Department of
Corrections, let me respond to Dr. Wohl’s concerns.  We strong-
ly agree that medical therapy in isolation (e.g. DOT) may be
only one of the contributing factors, and may have reduced
opportunities for better diets and illicit drug use. The authors
strongly feel that the adherence to medical pharmacotherapeu-
tic regimen is the key reason for improvement.  To test this
hypothesis, another study is planned of two groups, both of
which are incarcerated.  In systems that do not use DOT, but
have the other realities of prison life, rates of viral load improve-
ment match the community setting. Clearly, there are some sit-
uations and conditions where DOT can lead to aversive ele-
ments, so the initiation must be done with care and sensitivity.
In Florida, we have been using DOT for a long time, and our
staff and inmates report they are comfortable with it. Of the
2,700 inmates with HIV, the vast majority are on treatment
(2,250). Of the remainder, the overwhelming majority are not
captured by the guidelines (and we still use the more aggres-
sive 5-10,000 viral load cut-off for treatment). It is only a small
minority who refuse because of direct observed therapy.  Most
cite other reasons.
HEPP Editor’s Note: Clearly, there is a use for DOT in some
settings, but its success will vary between facilities. There is an
acute need for further study.
A point and counterpoint discussion of the use of Directly Observed Therapy for HIV treatment in the correctional setting.
*Speakers Bureau: Abbott Laboratories, GlaxoSmithKline and Merck & Co.
**Consultant & Speakers Bureau: Agouron Pharmaceuticals, Bristol- Myers Squibb , GlaxoSmithKline, Boehringer-Ingelheim/Roxane
Laboratories, Roche Pharmaceuticals, Merck & Co.
CME is Now Available Online at www.hivcorrections.org:
HEPP readers are now able to take HEPP News’ continuing medical education (CME) tests online at
http://www.HIVcorrections.org. Any internet browser will enable you to take the HEPP News CME tests every month.
Your test results will be registered with the Brown Medical School Office for Continuing Medical Education.  When you
pass the test, you can either download your CME certificate from the website or request Brown to send the certificate in
the mail. Try it out this week!
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Dr. Margaret Fischl, director of the Miami AIDS Clinical Research Unit, presented at the CROI (Feb. 7, 2001) her comparison of the out-
comes of treatment naïve ACTG subjects enrolled in antiretroviral treatment trials conducted both at the Miami AIDS Clinical Research
Unit and the Florida state prison (CROI Abstract 528).  Within the prison system, inmate-patients are administered antiretrovirals under
direct observation (DOT).  Fischl examined the viral load responses to study regimens among 50 prisoners receiving their study med-
ications via DOT and 50 AIDS Clinical Research Unit outpatients receiving study medication in the conventional, unobserved way. The
two groups were different demographically, with more of the incarcerated patients likely to be African American, Latino, male and to have
a history of injection drug use.  Further, the patients in prison had lower CD4 cell counts and higher viral loads.  After 24 weeks, 90% of
the prisoners had viral loads that were below 50 copies/mL while 77% of the free subjects achieved this goal at this time point.  These
differences in response rates remained out to 90 weeks of follow-up and were highly statistically significant.  In general, simpler regi-
mens of three drugs had better response rates than more complex four-agent combinations.
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Rapid Report:
By Joseph Bick, M.D.*, Director, HIV Treatment Services, California Medical Facility -Vacaville, California Department of Corrections
The Latest News From the 8th Conference on Retroviruses 
and Opportunistic Infections
ANTIRETROVIRAL CHEMOTHERAPY
Although promising data was presented on new NNRTIs and PIs
that are more potent and demonstrate improved resistance pro-
files, none of them are likely to be available for widespread use
within the coming year.  Likewise, fusion inhibitors and IL-2 require
further study before entering clinical practice.  What follows are
comments on a few abstracts that deal with simplified preparations
or pharmacokinetic (PK) enhancement of existing agents, which
are more immediately applicable to clinical care.  Full texts of all
conference abstracts are available at http://www.retroconfer-
ence.org/2001.
Abstracts 315 and 316 demonstrated Trizivir’s equivalent activity to
its components, AZT, 3TC, and abacavir. For selected patients, this
offers the simplicity of one pill twice daily .
Abstracts 318 and 319 supported the efficacy of the new extended
release formulation of ddI EC as compared to either standard ddI
or to other HAART regimens. Enteric-coated Didanosine is  easier
to take and leads to less drug-drug interactions than standard ddI
tablets.
Abstracts 332, 405, and 739 evaluated various dosing regimens
for the ritonavir (RTV) enhancement of amprenavir (AMP).
Combining data from these studies, the following regimens all
appear to have similar efficacy to the standard dosing of  AMP
1200 mg bid: AMP 600/RTV 100 bid, AMP 450/RTV 200 bid, and
AMP 1200/RTV 200 or 400 qd. All of the alternative regimens
decrease pill burden, increase C min (less opportunity for resis-
tance), decrease C max  (less toxicity) and lead to similar AUC.
The 450/200 option appears to have the best overall PK parame-
ters, and also obviates the need for dose modification when used
with NNRTIs.
Abstracts 334, 335, and 336 studied the PKs of ritonavir enhance-
ment of indinavir (IDV).  Pooling data from these three studies, the
standard dosing of IDV 800 mg tid had similar PK to IDV 800/RTV
100 bid, IDV 400/RTV 400 bid, and IDV 1200/RTV 200 qd.  The bid
and qd regimens provided less frequent dosing and eliminated the
necessity for dosing on an empty stomach.  Overall, the 400/400
option appeared to have the best PK parameters with the least
side effects.  
Abstracts 18 and 321 provided additional data on the once daily
use of emtricitibine (FTC), a NRTI with greater potency and pro-
longed half-life as compared to 3TC.  
In conclusion, virtually every HAART regimen can now be deliv-
ered in two daily doses, and there are an increasing number of
options for once daily therapies.  In the correctional setting, this will
increase adherence and simplify directly observed therapy for
those systems that chose to use it.
EPIDEMIOLOGY
The following four abstracts demonstrate the overwhelming ongo-
ing need for inmate peer education for all prisoners- whether
known to be infected or not.
G Abstracts 211 (NYC) and 212 (6 U.S. cities) both studied young
men who have sex with men (MSM) and found an alarming rate of
unprotected anal sex within the past six months (~50% of those
interviewed).  Both studies also found rates of HIV seropositivity
among African American men of approximately 30%--over twice as
high as those from all other racial/ethnic backgrounds. 
G Abstract 213 from Los Angeles found that those MSM who had
confidence that HAART decreases the risk of HIV transmission
were more likely to have had recent unprotected anal sex.  
G Abstract 261 from Amsterdam found a marked increased rate
of syphilis and gonorrhea (GC) among MSM. Among HIV seropos-
itive MSM, those who experienced a HAART induced rise in CD-4
and drop in viral load were found to then increase their rate of
unprotected sex with casual partners.  
TRANSMISSION
A number of studies have shown that HAART induced drops in HIV
viral load decrease the rate of transmission to seronegative part-
ners.  Abstract 221 from Thailand corroborated such prior studies
by finding no cases of transmission when the HIV viral load was
<1094.
Prior studies have shown that the presence of ulcerative genital
disease increases the transmission rate of HIV.  Abstract 222
demonstrated that the presence of GC urethritis also markedly
increases HIV transmission, reminding us of the unique opportuni-
ty that we have in correctional medicine to impact the spread of
disease by diagnosing and treating STDs.
Lastly, an important study from the Kaiser HMO system in
California (219) evaluated 416 individuals recently diagnosed with
HIV.  At the time of diagnosis, 44% already had CD-4 <200, with
19% <50.  Since HAART is most effective when instituted earlier in
the course of the disease (see abstracts 341 and 342), many
patients are being diagnosed too late for optimal benefit.
Furthermore, 40% of these newly diagnosed individuals had pre-
sented with known HIV risk factors at least 12 months before they
were eventually tested- reflecting missed opportunities for earlier
diagnosis and treatment.  Risk factors included oral infection,
pneumonia, unexplained fever >100, herpes zoster, seborrheic
dermatitis, night sweats, and unexplained weight loss.
Undiagnosed persons not only go untreated, but they also
unknowingly pass the virus to others. How often in our own cor-
rectional practices have we missed opportunities for earlier diag-
nosis?  
HCV ACCELERATES HIV AND VICE VERSA
The impact of HIV on HCV and vice versa has been the subject of
much debate. CROI reports contributed to the confusion. In a pop-
ulation of hemophiliacs, Dr Eric Daar found a close linear relation-
ship between HCV RNA level and abnormal liver function tests
(SGOT or ALT). The HCV viral load level (by branched-chain DNA)
appeared to independently predict an increased risk of HIV clinical
progression (abstract 35). This observation was confirmed in a
Swiss cohort, described in the Lancet (Greub G, et al. Lancet,
2000;356:1800-1805. However, a report by Sulkowski at CROI
contraindicated these findings, suggesting that risk of progression
was more linked to lack of access to medical care (for HIV) in his
cohort of African American patients who had HIV and HCV coin-
fection (abstract 34).
*No affiliations to disclose.
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Table 1.  Initial Treatment for Established HIV Infection
This table provides a guide to the use of available treatment regimens for patients with limited or no prior experience on HIV therapy.
In accordance with the established goals of HIV therapy, priority is given to regimens for which clinical trials data suggest the follow-
ing: sustained suppression of HIV plasma RNA (particularly in patients with high baseline viral load) and sustained increase in CD4+ T
cell count (in most cases over 48 weeks), and favorable clinical outcome (i.e. delayed progression to AIDS and death).  Particular
emphasis is given to regimens that have been compared directly with other regimens that perform sufficiently well with regard to these
parameters to be included in the "Strongly Recommended" category.  Additional consideration is given to the regimen’s pill burden,
dosing frequency, food requirements, convenience, toxicity, and drug interaction profile compared with other regimens.  
It is important to note that all antiretroviral agents, including those in the "Strongly Recommended" category, have potentially serious
toxic and adverse events associated with their use.  The reader is strongly encouraged to consult the HHS HIV Treatment Guidelines
(available at www.hivatis.org) while formulating an antiretroviral regimen.
Antiretroviral drug regiments are comprised of one choice each from columns A and B.  Drugs are listed in alphabetical, not priority,
order.
a See Guidelines page 16 for more information on optimizing protease inhibitor exposure with ritonavir.**
b Based on expert Opinion**
c Saquinavir-SGC, soft-gel capsule (Fortovase); Saquinavir-HGC. Hard-gel capsule (Invirase).**
d Pregnant women may be at increased risk for lactic acidosis and liver damage when treated with the combination of stavudine and
didanosine. This combination should be used in pregnant women only when the potential benefit clearly outweighs the potential risk.
e This category includes drugs or combinations for which information is too limed to allow a recommendation for or against use.**
f Zidovudine monotherapy may be considered for prophylactic use in pregnant women with low viral load and high CD4+ T cell counts
to prevent perinatal transmission, as discussed under Considerations in the Pregnant Woman" in the Guidelines.
g Use of Saquinavir-HGC (Invirase) is not recommended, except in combination with ritonavir.
**Changes from last year’s guidelines are starred.
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Strongly Recommended
Recommended as
Alternatives
No Recommendation:
Insufficient Datae
Not Recommended: 
Should Not Be Offered
Column A
Efavirenz (Sustiva, EFV)
Indinavir (Crixivan, IDV)
Nelfinavir (Viracept, NFV)
**Ritonavir (Norvir, RTV)+ Indinavirab
**Ritonavir/Lopinavir (Kaletra)a
Ritonavir + Saquinavira (SGCc or HGC)
Column A
Abacavir (Ziagen, ABC)
Amprenavir  (Agenerase, AMP)
Delavirdine (Rescriptor, DLV)
Nelfinavir + Saquinavir
Nevirapine (Viramune, NVP)
Ritonavir
Saquinavir-SGC
Trizivir (Abacavir, Lamivudine, Zidovudine)
Hydroxyurea in combination with 
antiretroviral drugs
**Ritonavir + Amprenavira
Ritonavir + Nelfinavira
All monotherapies, whether from 
Column A or Bf
Column A
Saquinavir-HGCg
Column B
Stavudine (Zerit, d4T)+ Didanosine (Videx, ddI, 
ddi EC)d
Stavudine + Lamivudine (Epivir, 3TC)
Zidovudine (Retrovir, ZDV) + Didanosine
Zidovudine + Lamivudine (Combivir)
Column B
Didanosine + Lamivudine
Zidovudine + Zalcitabine (Hivid, ddC)
Column B
Stavudine + Zidovudine
Zalcitabine + Didanosine
Zalcitabine + Lamivudine
Zalcitabine + Stavudine
( HEPPigram continued on page 8 )
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American Correctional Health
Services Multidisciplinary
Training Conference
March 15-18, 2001
Atlanta, Georgia
Call: 877.918.1842
Visit: www.corrections.com/
achsa/conferences.html
Implementing HIV Treatment
Guidelines in Corrections
Panel organized by HEPP at the
National AIDS Update Conference
(March 20-23) 
March 21, 2001
11:00am-12:30pm
San Francisco, California
Conference sponsored by amfAR
For information on the panel, 
Call: 401.863.2180
Email: bstubb@Brown.edu
For information on the conference,
Call: 514.874.1998
Visit: http://www.nauc.org
United States Conference 
on AIDS (USCA)
September 13-16, 2001
Fort Lauderdale, Florida
Abstract Deadline: April 2, 2001
Call: 202.483.6622
Email: info@nmac.org
Visit: www.usca.org
Clinical Updates in Correctional
Health Care: 6th Semi-Annual
Spring Educational Conference 
May 5-8, 2001 
Las Vegas, Nevada 
Sponsored by: NCCHC and ACHP
Call: 773/880.1460
Fax: 773/880.2424
Visit: http://www.ncchc.org/
conference/clinical.html
Save the 
Dates
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Other News . . .
We have a new sign-up 
number, so tell your 
colleagues to sign up for
HEPP News by calling
1.800.748.4336. 
(You can also sign up on 
the website at 
www. hivcorrections.org or 
by faxing 1.617.770.3339 
or emailing 
hepp@corrections.net.)
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Resources
Websites:
*Updated DHHS HIV/AIDS Treatment
Guidelines
http://www.hivatis.org
8th Conference on Retroviruses and
Opportunistic Infections
http://www.retroconference.org/2001
Medscape Coverage of the 8th CROI
http://www.medscape.com/conferences/Retro
virus2001
Medscape HIV/AIDS Online
http://www.medscape.com/Home/Topics/
AIDS/AIDS.html
HIV Treatment Websites:
HIV/AIDS Treatment Information Service
http://www.hivatis.org
HIV Insite
http://hivinsite.ucsf.edu/
AEGiS: the largest HIV/AIDS resource on
the internet
http://www.aegis.com
The Body: An AIDS and HIV information
Resource
http://www.thebody.com 
Table 2.  Indications for the Initiation of Antiretroviral Therapy in the
Chronically HIV-1 Infected Patient
Clinical Category
Symptomatic
Asymptomatic, 
AIDS
Asymptomatic
Asymptomatic
Asymptomatic
CD4+ T Cell Count
Any value
<200/mm3
>200/mm3 but 
<350/mm3
>350/mm3
>350/mm3
Plasma HIV RNA
Any value
Any value
Any value
>30,000 (bDNA) 
or >55,000 (RT-PCR)
<30,000 (bDNA) 
or <55,000 (RT-PCR)
Recommendation
Treat
Treat
Treatment should generally
be offered, though contro-
versy exists.*
Some experts would rec-
ommend initiating therapy,
recognizing that the 3-year
risk of developing AIDS in
untreated patients is >30%.
In the absence of very high
levels of plasma HIV RNA,
some would defer therapy
and monitor the CD4+ T
cell count and level of plas-
ma HIV RNA more fre-
quently.  Clinical outcomes
data after initiating therapy
are lacking.
Many experts would defer
therapy and observe, rec-
ognizing that the 3-year risk
of developing AIDS in
untreated patients is <15%.
*Clinical benefit has been demonstrated in controlled trials only for patients with CD4+ T cells 
<200/ mm3. However, most experts would offer therapy at a CD4+ T cell threshold <350/mm3. All deci-
sions to initiate therapy should be based on prognosis for disease-free survival in the absence of treat-
ment, as determined by the CD4+ T cell count and level of plasma HIV RNA shown in Table 5, the
potential benefits and risks of therapy shown in Table 4, and the willingness of the patient to accept ther-
apy.  For further information, see "Considerations for Initiating Therapy in the Patient with Asymptomatic
HIV Infection," page 6 of the HHS Guidelines. 
These tables were taken from US Dept of Health and Human Services. Guidelines for the use of anti-
retroviral agents in HIV-infected adults and adolescents. Washington, DC: US Dept of Health and Human
Services; February 2001. P44 and 38. Online at http://www.hivatis.org.
Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physicians Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. A
minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through 
Feb. 28, 2002. The estimated time for completion of this activity is one hour and there is no fee for participation.
1.  Which of the following statements is false?
a) T memory cells act as a long-lived reservoir for HIV 
infection. 
b) HAART can dramatically interrupt the replication of HIV in 
activated T cells 
c) Patients who have been started on ART should stop 
treatment if their CD4 T cell count is above 350.
d) Adherence to HAART can "freeze" HIV in time, preventing 
the evolution of new resistance mutations.
e) The decision to modify HIV treatment guidelines was based 
on  evidence of long-term drug toxicity 
2.  When should plasma RNA be measured?
a) Patient presents with syndrome consistent with acute HIV 
infection.
b) As part of initial evaluation of newly diagnosed HIV 
infection.
c) 2-8 weeks after initiation of antiretroviral therapy.
d) 3-4 months after initiation of antiretroviral therapy.
e) Patient presents with clinical evidence or significant decline 
in CD4+ T cell count.
f) All of the above
g) None of the above
3.  The new guidelines indicate that physicians should delay the
initiation of HIV treatment until absolute CD4 T cell counts are
_____ and/or HIV RNA viral loads are ______. 
a) CD4 T cell count  <500 and/or HIV RNA viral load >5000.
b) CD4 T cell count  <450 and/or HIV RNA viral load >30,000.
c) CD4 T cell counts <350 and/or HIV RNA viral load >55,000.
d) CD4 T cell count >350 and/or HIV RNA viral load >55,000.
4.  Which of the following are true? 
a) Response to therapy should be indicated by a one-log 
reduction in viral load.
b) Viral resistance testing should be included in HIV treatment 
management.
c) Ultrasensitive viral load testing should be included in HIV 
treatment management.
d) All of the above.
e) None of the above.
5.  When presented with an asymptomatic patient with AIDS,
CD4+ T cell <200/mm3 and plasma RNA of 50,000, you should:
a) Treat.
b) Consult an expert and consider treatment.
c) Obtain a genotype.
d) Defer treatment.
6.  CD4+ T cell count and viral load should be monitored every
___ months because patients often experience sudden declines.
a) 2
b) 3
c) 6
d) 12
BROWN MEDICAL SCHOOL   OFFICE OF CONTINUING MEDICAL EDUCATION   BOX G-A2    PROVIDENCE, RI 02912
The Brown Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical 
education activities for physicians.  
The use of the Brown Medical School name implies review of the educational format and material only.  The opinions, recommendations 
and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or speak for the 
Brown Medical School.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660 or 
register online at www.hivcorrections.org. Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree ____________________
Address ____________________________________________________________________________________________
____________________________________________________________________________________________________
City ____________________________________________________ State ________ Zip ________________________
Telephone ________________________________________________ Fax ______________________________________
HEPP News Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1     
Spotlight 5  4  3  2  1   5  4  3  2  1  
HEPPigram 5  4  3  2  1   5  4  3  2  1
Save the
Dates 5  4  3  2  1   5  4  3  2  1
2. Do you feel that HEPP News helps you in your work?
Why or why not?
3. What future topics should HEPP News address?
4. How can HEPP News be made more useful to you?
5. Do you have specific comments on this issue?
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CME is now available ONLINE at www.hivcorrections.org
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